Nucleic acids research 33 , 68846894, doi:10.1093/nar/gki1000 (2005)
For Wegovy, current prescribing information states that escalation is designed to reduce gastrointestinal adverse reactions and allows clinicians to consider delaying escalation when a dose is not tolerated
At the start of the month, there are now more than 3,600 gastroparesis lawsuits pending in federal court, along with 86 blindness lawsuits
Weight loss during GLP-1 treatment may be associated with changes in how some people experience sweating, though this varies between individuals and scientific evidence for direct effects on thermoregulation is limited
Chua S, Lee FY, Tsai TH, Sheu JJ, Leu S, Sun CK